Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX008 adjunctive therapy in Dravet syndrome patients receiving stiripentol
2016-000474-38Phase 3Completed
- Sponsor
- Zogenix, Inc.
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in Dravet syndrome (3 cohorts), sponsored by Zogenix, Inc. Primary endpoint: Change in mean convulsive seizure frequency per 28 days. Started Mar 2016; status: completed.
02
Drugs
fenfluramine
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on 2016-000474-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000474-38.